Vividion Therapeutics

5820 Nancy Ridge Dr.
San Diego
California
United States

Email: information@vividion.com

Show jobs for this employer

About Vividion Therapeutics


Vividion Therapeutics is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide ligand and target discovery. Headquartered in San Diego, CA, Vividion Therapeutics is a private, biotechnology company founded in 2014 with seed financing from Cardinal Partners as a spin out from the labs of Dr. Benjamin Cravatt, Dr. Phil Baran and Dr. Jin-Quan Yu at TSRI. In 2017, Vividion launched with $50 million in Series A financing from ARCH Venture Partners, Versant Ventures and founding investor Cardinal Partners

YEAR FOUNDED:

2017

LEADERSHIP:

Founders:

* Benjamin F. Cravatt III, Ph.D., Professor and Co-Chair, Department of Molecular Medicine, the Skaggs Institute for Chemical Biology at The Scripps Research Institute

* Phil S. Baran, Ph.D., Professor, Darlene Shiley Professor of Chemistry, Department of Chemistry, the Skaggs Institute for Chemical Biology at The Scripps Research Institute

* Jin-Quan Yu, Ph.D., Frank and Bertha Hupp Professor of Chemistry, Department of Chemistry, The Scripps Research Institute

* John K. Clarke, Managing General Partner, Cardinal Partners

CAREER:

Please click here for Vividion's job opportunities.

10 articles with Vividion Therapeutics